Pier Capital LLC Grows Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Pier Capital LLC grew its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 43.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 87,497 shares of the medical equipment provider’s stock after acquiring an additional 26,479 shares during the quarter. Pier Capital LLC owned about 0.13% of Lantheus worth $7,827,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the stock. Raymond James Financial Inc. acquired a new position in Lantheus in the 4th quarter valued at about $36,183,000. Groupama Asset Managment purchased a new stake in shares of Lantheus during the third quarter worth about $439,000. Swedbank AB raised its position in shares of Lantheus by 53.3% in the fourth quarter. Swedbank AB now owns 1,107,243 shares of the medical equipment provider’s stock valued at $99,054,000 after buying an additional 385,000 shares during the last quarter. Keybank National Association OH purchased a new position in shares of Lantheus during the fourth quarter valued at approximately $27,526,000. Finally, Janus Henderson Group PLC boosted its position in Lantheus by 7.7% during the third quarter. Janus Henderson Group PLC now owns 3,588,571 shares of the medical equipment provider’s stock worth $393,844,000 after acquiring an additional 257,022 shares during the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have weighed in on LNTH. Truist Financial boosted their price target on Lantheus from $120.00 to $127.00 and gave the company a “buy” rating in a report on Thursday, February 27th. JMP Securities reiterated a “market outperform” rating and issued a $112.00 target price on shares of Lantheus in a research note on Tuesday, January 14th. The Goldman Sachs Group assumed coverage on Lantheus in a research note on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price target on the stock. Finally, B. Riley lowered their price target on Lantheus from $127.00 to $122.00 and set a “buy” rating for the company in a report on Friday. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Lantheus has an average rating of “Moderate Buy” and a consensus price target of $129.43.

Insider Transactions at Lantheus

In related news, Director Mary Anne Heino sold 53,107 shares of the company’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the sale, the director now directly owns 440,399 shares of the company’s stock, valued at approximately $41,551,645.65. This represents a 10.76 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director James H. Thrall sold 1,000 shares of the firm’s stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total value of $94,760.00. Following the completion of the transaction, the director now directly owns 33,207 shares in the company, valued at $3,146,695.32. This trade represents a 2.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 64,109 shares of company stock valued at $6,110,806 over the last 90 days. Corporate insiders own 1.50% of the company’s stock.

Lantheus Trading Up 1.8 %

LNTH stock opened at $99.44 on Tuesday. The company has a market cap of $6.81 billion, a PE ratio of 16.55 and a beta of 0.38. The stock has a 50-day moving average price of $92.77 and a two-hundred day moving average price of $96.47. Lantheus Holdings, Inc. has a 12-month low of $57.92 and a 12-month high of $126.89.

Lantheus (NASDAQ:LNTH) last issued its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.23). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The firm had revenue of $391.11 million for the quarter, compared to analysts’ expectations of $376.61 million. Equities analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.